These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 10086733)

  • 41. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients.
    Kansal R; Deeb G; Barcos M; Wetzler M; Brecher ML; Block AW; Stewart CC
    Am J Clin Pathol; 2004 Apr; 121(4):512-25. PubMed ID: 15080303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of CD34 on human B cell precursors.
    Schmitt C; Eaves CJ; Lansdorp PM
    Clin Exp Immunol; 1991 Jul; 85(1):168-73. PubMed ID: 1712682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
    Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
    Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL.
    Ciudad J; San Miguel JF; López-Berges MC; García Marcos MA; González M; Vázquez L; del Cañizo MC; López A; Van Dongen JJ; Orfao A
    Br J Haematol; 1999 Mar; 104(4):695-705. PubMed ID: 10192428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Thulasi Raman R; Anurekha M; Lakshman V; Balasubramaniam R; Ramya U; Revathi R
    Leuk Lymphoma; 2020 Aug; 61(8):1974-1980. PubMed ID: 32281503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.
    Dworzak MN; Fritsch G; Fröschl G; Printz D; Gadner H
    Blood; 1998 Nov; 92(9):3203-9. PubMed ID: 9787156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
    Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mesenchymal stem cells promote leukaemic cells aberrant phenotype from B-cell acute lymphoblastic leukaemia.
    Rodríguez-Pardo VM; Aristizabal JA; Jaimes D; Quijano SM; de los Reyes I; Herrera MV; Solano J; Vernot JP
    Hematol Oncol Stem Cell Ther; 2013; 6(3-4):89-100. PubMed ID: 24161606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.
    Zhou T; Karrs J; Ho T; Doverte A; Kochenderfer JN; Shah NN; Yuan CM; Wang HW
    Cytometry B Clin Cytom; 2023 Jul; 104(4):294-303. PubMed ID: 36433814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Girase K; Verma S; Arolkar G; Dasgupta N; Narula G; Shetty D; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
    Br J Haematol; 2022 Jan; 196(2):374-379. PubMed ID: 34476808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human B-cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data.
    Bagwell CB; Hill BL; Wood BL; Wallace PK; Alrazzak M; Kelliher AS; Preffer FI
    Cytometry B Clin Cytom; 2015; 88(4):214-26. PubMed ID: 25850810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
    Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
    Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia.
    Wilson K; Case M; Minto L; Bailey S; Bown N; Jesson J; Lawson S; Vormoor J; Irving J
    Haematologica; 2010 Apr; 95(4):679-83. PubMed ID: 19951974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
    Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
    Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
    Sidhom I; Shaaban K; Soliman S; Ezzat S; El-Anwar W; Hamdy N; Yassin D; Salem S; Hassanein H; Mansour MT
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):111-20. PubMed ID: 20029466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
    Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD19-negative B-lineage acute lymphoblastic leukemia: A diagnostic and therapeutic challenge.
    Bansal S; Sharma U; Jain A; Sharma R; Yagnik B
    Indian J Pathol Microbiol; 2017; 60(4):596-598. PubMed ID: 29323085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The CD24 antigen discriminates between pre-B and B cells in human bone marrow.
    Duperray C; Boiron JM; Boucheix C; Cantaloube JF; Lavabre-Bertrand T; Attal M; Brochier J; Maraninchi D; Bataille R; Klein B
    J Immunol; 1990 Dec; 145(11):3678-83. PubMed ID: 1700990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.